Amicus Therapeutics (FOLD) Misses Q2 EPS by 7c
Get Alerts FOLD Hot Sheet
Revenue Growth %: +31.1%
Financial Fact:
Interest expense: -1.52M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Amicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.40), $0.07 worse than the analyst estimate of ($0.33).
2016 Financial Guidance
Cash, cash equivalents, and marketable securities totaled $214.2 million at June 30, 2016. The Company’s balance sheet was strengthened during the second quarter of 2016 with $57.8 million in net proceeds under the existing at-the-marketing (ATM) financing facility and an additional $30 million in debt under an existing debt facility. Following the second quarter close, the Company raised an additional $39.3 million in net proceeds through the ATM facility and has raised the full $100 million allotted for the ATM facility. The Company expects to remain within the original 2016 net cash spend guidance of between $135 million and $155 million.
For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) down despite beating Q1 estimates on top and bottom lines
- Parke Bancorp (PKBK) Reports Q1 EPS of $0.51
- Super Micro Computer (SMCI) Falls 6%
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!